World’s first lung cancer vaccine begins human trials

A 67-year-old patient at the University College London Hospital is the first to receive the first-ever lung cancer vaccine.  German biotech firm BioNTech developed this mRNA-based inoculation called BNT116. The vaccine works by activating the immune system so that it recognizes and combats cancer cells. READ: AMICA maps human immune system with AI The researchers